Dr Lal PathLabs Ltd achieved a significant milestone by hitting a fresh record high of ₹2,035 on September 16, 2026, according to reports from The Economic Times. However, the pharma industry stock failed to maintain this momentum and could not hold the peak price levels. The stock's inability to sustain the record high suggests some technical resistance or profit-taking pressure in the market.
Despite the recent pullback, technical indicators suggest the rally may continue in the coming weeks. As reported by The Economic Times, short-term traders can look to buy the stock for a target above ₹2,200 levels in the next 3-4 weeks. The stock is currently trading above key moving averages, showing positive technical indicators that support the potential for further upward movement.
Market experts recommend implementing a stop loss at ₹1,920 to manage risks during this period, according to The Economic Times. This technical level serves as a protective measure for investors while allowing participation in the potential upward movement toward the target price of ₹2,200. The stop loss placement above the 20-day moving average provides a balanced approach to risk management.
The stock's ability to find support above the 20-day moving average indicates underlying strength despite the recent volatility. As reported by The Economic Times, the chart pattern suggests that the rally is likely to continue, though maintaining the momentum above ₹2,035 will be crucial for sustaining the upward trajectory. The pharma sector's performance will continue to influence Dr Lal PathLabs stock movement in the near term.
